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1. Introduction 
Life expectancy increases in developed countries and results in a high prevalence of age-
related diseases namely in women. Elderly subjects generate a huge demand on the social 
and health services linked to their disability and dependence. Besides the own effects of 
aging, the estrogenic deficiency, especially during menopause, is the major cause of 
degenerative diseases such as osteoporosis, skin aging, Alzheimer’s disease and 
osteoarthritis (OA) (Antonicelli et al., 2008; Candore et al., 2006; Elders, 2000; Felson & 
Nevitt, 1998; Pietschmann et al., 2008; Stovall & Pinkerton, 2008). OA is a worldwide public 
health problem which may affect different sites of the skeleton. In the Western world, at 
least 10% of the population has OA symptoms and 80% of the population will be potentially 
affected after the age of 70 years. Knee OA represents one of the major causes of morbidity 
and disability in relation to the worsening of quality of life (Elders, 2000). Pathogenesis of 
knee OA involves multiple factors including gender, weight, and genetics. Although age-
dependent degenerative pathologies, especially OA, involve complex mechanisms in which 
the imbalance of the cytokines/growth factors plays a crucial role, it is more and more 
obvious that estrogens participate, with their receptors and modulators, to all of these 
diseases affecting connective tissues (Calleja-Agius & Brincat, 2009). Estrogens are steroidal 
hormones irreversibly synthesized from androgens via a crucial enzyme of steroidogenesis 
called aromatase, a member of cytochrome P450 superfamily, encoded by the CYP19 gene 
and being expressed in both sexes of many species (Simpson, 2003).  
Although non genomic action of estrogens is now recognized but these sexual hormones act 
often as signaling molecules that exert their effects by binding to estrogen receptors (ER) 
within the cells.  
The estrogen-receptor complex interacts then with DNA to change the expression of 
estrogen-responsive genes. The two known estrogen receptors, ER and ER, are present in 
numerous tissues other than those associated with reproduction, including bone, liver, 
heart, brain and cartilage and being selectively expressed in some targets; for instance ER is 
selectively expressed in lung and intestine. The presence of ER and ER was detected in 
articular chondrocytes of different species, especially in human, rat, pig, cow and rabbit 
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(Classen et al., 2001; Dayani et al., 1988; Oshima et al., 2007; Ushiyama et al., 1999). The 
action of 17-estradiol (17-E2) on the cartilage appears to be intimately linked to the sex of 
individuals since it was shown that the binding capacity of 17-E2 to its receptor was 
significantly higher in chondrocytes derived from male rather than female individuals 
(Nasatzky et al., 1994). In addition, 17-E2 can stimulate the nuclear expression of its own 
receptors in chondrocytes and create therefore a loop that reinforces the activation effects of 
the hormone in this cell type (Richmond et al., 2000). Moreover, a strong correlation was 
found between the polymorphism of ESR1 gene encoding ER and increased risk of OA in 
several populations (Bergink et al. 2003; Valdes et al., 2006). All these observations tend to 
prove that the cartilage is an estrogen-sensitive tissue, in which 17-E2 would be likely to 
play a preponderant role in regulating chondrocyte homeostasis in joint diseases such as 
OA. 
Even thought hormone replacement therapy (HRT) is the most efficient treatment against, at 
least, some of the degenerative pathologies mentioned above but studies confirm that risks 
linked to HRT can exceed the discounted benefits. As a consequence, it becomes important 
to address the question of the age-associated disorders and to find new targets to treat them. 
Selective Estrogen Receptor Modulators (SERM) like tamoxifen, raloxifen, fulvestrant and 
genistein have shown to be useful and attracted the attention of researchers (Cotter & 
Cashman, 2003; Khalil, 2010; Riggs & Hartmann 2003).  A characteristic that distinguishes 
these substances from pure receptor agonists and antagonists is that their action is different 
in various tissues, thereby giving the possibility to selectively inhibit or stimulate estrogen-
like action in various tissues. For instance tamoxifen (a first generation SERM) and raloxifen 
have been clinically used as antagonists of ER against breast cancer while they could be 
potentially agonists in bone and growth plate (Chagin et al, 2007; Nilsson et al, 2003). It has 
been proposed that these SERM could be used to replace natural estrogens to induce growth 
plate fusion reducing thereby the final height in girls expected to achieve extreme tall 
stature. Moreover, phytoestrogens (flavones, isoflavones, lignans) have aroused much 
interest as natural SERM and potential substitutes in the hormonal treatment of post-
menopausal women, but they require much further investigation regarding their 
mechanism(s) of action and their safety (Dodin et al, 2003). 
2. Estrogen synthesis and action 
2.1 Estrogen synthesis via aromatase 
Estrogens are steroidal hormones composed from 18 atoms of carbon and produced 
essentially in gonads, ovary and testis, but also in non reproductive tissues such as bone and 
adipose tissue. These lipophilic compounds irreversibly synthesized from androgens via a 
crucial enzyme of steroidogenesis called aromatase, a member of cytochrome P450 
superfamily, encoded by the CYP19 gene and being expressed in both sexes of many 
species. In pre-menopoausal women, estrogens such as 17-E2 (the more estrogenic) and 
estrone are synthesized in ovary during follicular phase whereas estriol being produced 
essentially by placenta during pregnancy. After menopause, when ovary activity 
disappears, production of 17-E2 from testosterone via aromatase is assumed by peripheral 
tissues like liver, adipose tissue, bone, vascular endothelium, chondrocyte and synovial cells 
(Simpson, 2003; Takeuchi et al., 2007; Tanko et al., 2008). Consequently, circulating 17-E2 
concentrations decrease drastically to 0.04-0.21 nM to reach those found in man (Chambliss 
& Shaul, 2002). Thus, estrogen action being localized and switch from endocrine to auto-, 
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intra- and/or paracrine actions. Due to their lipophilic feature, estrogen can diffuse into the 
cell through plasma membrane and induce estrogen-dependent intracellular signaling 
pathways and/or bind the intracellular receptors especially ER stimulating an estrogen-
dependent response in target cells. 
2.2 ER structure 
In mammals, estrogens produced locally in different tissues, may exert various biological 
effects but are also responsible of the development of some pathological process such as 
hormone-dependent cancers. Estrogens exert their physiological and pathological effects 
through specific receptors considered as nuclear factors by binding target genes at a specific 
cis sequence called Estrogen Responsive Element (ERE).  
The first study on estrogen receptor, published by Toft & Groski in 1966, demonstrated that 
a specific protein of rat uterus was able to bind specifically estrogens. Later, the gene of this 
protein has been cloned (Walter et al., 1985) and sequenced (Green et al., 1986) from 
mammal cancer epithelium (MCF-7) of a patient suffering from breast cancer. This protein is 
now recognized as ER. A second gene (ER) has been also cloned from a cDNA library of 
the rat prostatic cells (Kuiper et al., 1996), being expressed selectively in some tissues and 
presenting more affinity for phytoestrogens. 
It is now established that the majority of the normal and pathological action of estrogens 
is generally mediated through these two estrogen receptors ERand ER which are 
members of nuclear receptor super family including progesterone, glucocorticoids, 
androgens and vitamin D receptors (Nuclear Receptor Nomenclature Committee, 1999; 
Germain et al., 2006; Mangelsdorf et al., 1995). In human, ERis encoded by ESR1 gene 
located on chromosome 6 (6q25.1) whereas ER is encoded by ESR2 gene located on 
chromosome 14 (14q23.2). Both ESR1 and ESR2 genes encoding the estrogen receptor may 
undergo alternative splicing of mRNA. Most of these transcripts differ only in their 5'UTR 
(Untranslated Region) and will be mainly translated into a long form of ER, recognized as 
ER66 (Flouriot et al., 1998). However, a second form of ER protein, derived from 
alternative splicing of exon 1A mRNA or a site of alternative translation initiation (AUG 
codon 174) was discovered and named ER46 (Barrailler et al. 1999; Flouriot et al., 2000). 
After translation, the 46 kDa isoform is truncated of the 173 first amino acids of the long 
form of 66 kDa. ER46 protein is thus composed of 422 amino acids, whereas ER66 has 
595 amino acids. Both ER isoforms are capable of inducing a physiological response after 
ligand binding. The 46 kDa isoform can heterodimerize with ER66 and competitively 
inhibit the functions of ligand-independent trans activation of the long form of the receptor 
(Flouriot et al., 2000). 
ERand ER530 amino acids) are structurally organized in six distinct functional domains 
(A to F) (Fig. 1). There are structural and functional similarities more or less strong between 
ER and ER whose homology percentages vary significantly depending on the area 
considered. DNA binding domain (DBD) is conserved at about 97%, which means that both 
receptors can bind the same cis nucleotide sequences and thus activate transcription 
ofidentical target genes. However, there is only 55% homology at the level of ligand 
binding domain (LBD), indicating that ER and ER have different ligand binding 
specificity. Finally, ER has only a truncated form of ligand-independent trans activation 
domain (AF-1), thus limiting its trans activation ability (Hall & McDonnell, 1999; Pearce & 
Jordan, 2004).  
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Fig. 1. Structures and functional domains of estrogen receptors (ER) 
Structures, functional domains and sequence homology percentage (italic) of  and  isoforms. AF-1, 
ligand-independent trans activation domain; AF-2, ligand-dependent trans activation domain; 
DBD, DNA Binding Domain; hsp90, heat-shock protein 90; LBD, Ligand Binding Domain; NLS, Nuclear 
Localization Signal. These 3 isoforms, ERα46, ERα66 and ER┚ are expressed in articular chondrocytes. 
2.3 Genomic and non genomic action of estrogen 
It is well established that estrogens act at target genes level to modulate their transcription 
via ER binding, so playing a transcriptional factor role recognized as ligand-dependent 
mechanism (Jensen & DeSombre, 1973). However, estrogen action becomes more 
complicated following the discovery of ER, or different ER and ER isoforms but also 
with the identification of new plasma-associated membrane receptors. ER and ER 
regulate thus estrogen-dependent genes expression through two distinct mechanisms: ERE-
dependent genomic pathway and ERE-independent genomic pathway. 
2.3.1 ERE-dependent genomic pathway 
In this mechanism ER and ER, following ligand fixation (estrogen, phytoestrogen, SERM), 
are subjected to homo- or hetero-dimerization, then ligand/ER complex move to the nucleus 
to bind directly ERE cis element (AGGTCAxxxTGACCT) (Hall et al., 2001) present in the 
promoter of target genes (Fig. 2). The determination of consensus sequences ERE and the 
fixation of ER will help to recruit transcriptional factors such as FOXA1 (Forkhead Box A1) or 
GATA4 (GATA binding protein 4), which will first ensure the chromatin remodeling 
necessary for ER binding. Ligand binding also allows the recruitment of transcription cofactors 
such as SRC-1 (Steroid Receptor Coactivator-1), GRIP-1 (Glucocorticoid Receptor Interacting 
Protein-1), CBP (CREB Binding Protein)/p300, or TRAP220 (Thyroid Hormone Receptor 
Activating Protein 220) (McKenna et al., 1999). The classic genomic pathway requires the 
activity of the two trans activation domains AF-1 and AF-2 that will allow the sequential and 
cyclic recruitment of different co-factors of transcription (Metivier et al., 2001). 
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2.3.2 ERE-independent genomic pathway 
In this pathway, ERs will follow the classical mechanism described above except that they 
interact at the nuclear level with various transcriptional activator or repressor factors to 
regulate transcription of many estrogen-dependent genes that lack an ERE (Kushner et al., 
2000; Paech et al., 1997; Sabbah et al., 1999; Safe, 2001). 
Indeed, most estrogen-dependent genes have not necessarily in their regulatory regions a 
consensus ERE sequence. Therefore, estrogen will be involved in signaling pathways called 
ERE-independent which imply an interaction of ER with promoter of target gene through 
other transcription factors. In this case, the region of the receptor DBD does not bind to 
DNA, but participates in protein-protein interactions or recruitment of co-regulatory 
proteins to regulate expression of many genes. This mechanism of action is frequently used 
by nuclear receptors, which significantly complicates the decrypting of the effects induced 
by the ER (Gottlicher et al., 1998).  Many of ER/protein interactions, which occur in cells to 
regulate transcription of many target genes, are composed for example of ER/AP-1 complex 
(c-Fos/c-Jun) (Ascenzi et al., 2006; Duan et al., 2008; Kushner et al. 2000; Matthews et al. 
2006 ; Paech et al., 1997, Uht et al 1997; Webb et al., 1999,), ER/Sp complex (Ascenzi et al., 
2006; He et al., 2005; Kim et al., 2003; Saville et al., 2000; Stoner et al., 2004), and ER/NF-B 
complex (Galien & Garcia, 1997; Stein & Yang, 1995). This latter is the only known 
mechanism of transcriptional repression induced by ER (Fig. 2). 
For instance, after being activated by 17-E2 binding, ER interact with the transcription 
factor NF-B to control the transcriptional repression of certain genes such as IL-6 gene, 
which is involved in cartilage catabolism. Furthermore, in articular chondrocytes, it has been 
shown that 17-E2 can counteract the effects of IL-1 by inhibiting nuclear translocation of 
the p65 subunit of NF-B and therefore, binding of p65 to inducible nitric oxide synthase 
(iNOS) gene promoter (Richette et al., 2007). In addition, it has been suggested that ER and 
NF-B compete for binding to the same transcriptional co-activators (p300/CBP and PCAF), 
and that in the case of activation of transcription by 17-E2 through ER, the pool of these co-
activators is mobilized predominantly by ER at the expense of NF-B (Ansari & Gandy, 
2007).  
Therefore, estrogen/ER complex allows developing multiple physiological responses 
following hormonal stimulation by different signaling pathways and inter-connections with 
different trans factors and cis elements at the DNA level of target cells. 
2.3.3 Non genomic signaling pathway 
The non-genomic effects are defined as any action that does not involve transcriptional 
activity resulting from direct or indirect interaction of a nuclear receptor with the regulatory 
sequences of hormone-regulated genes. These effects are very rapid (in the order of several 
seconds to several minutes), incompatible with gene activation or protein synthesis. The 
effects of non-genomic estrogen receptors are often linked to signaling pathways that 
involve G protein-coupled receptors, ion channels or receptors linked to enzymes. 17-E2 
could modulate intracellular calcium or cAMP production and activate MAPK/ERK, PLC, 
PKA, or that of PI3K signaling pathways (Marino et al., 2002) (Fig 2). All these effects are not 
modified by inhibitors of transcription (actinomycin D) or translation (cycloheximide) (Losel 
& Wehling, 2003), confirming that they do not depend on a genomic action. In 1998, Beyer 
and Raab, by coupling 17-E2 to BSA (Bovine Serum Albumin), thereby preventing it from 
crossing the plasma membrane, observed that 17-E2 modulates intracellular calcium. Thus,  
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Fig. 2. Different pathways involved in estrogen receptors (ER) signaling. 
These different pathways occur in estrogen sensitive cells including ERE-dependent genomic, ERE-
independent genomic (via Sp1, AP-1 and NF-B) and membrane associated ER/G protein mechanisms. 
NF-B pathway is the only inhibitory mechanism. In articular chondrocytes ER66 homodimer 
complex binds predominantly Sp1 proteins to activate GC-box mediated trans activation of target genes 
such as Uridine diphospho-glucose deshydrogenase (UDPGD) and type II collagen (type II Col). Other 
mechanisms mediated by ER46 , ER, ER and ER homo- and/or  heterodimer and finally 
membrane associated ER /protein G need to be elucidated in articular chondrocytes. Note that 17-E2 
production from androgens like testosterone takes place via aromatase (CYP19) locally (intracrine effect) 
or in other cells (paracrine or endocrine effects). Adc, Adenylate cyclase; AP-1, Activating Protein-1; 
ERK, Extracellular signal Regulated Kinase; ERE, Estrogen Responsive Element; G, G protein; Hsp-90; 
Heat-shock protein 90; MAPK, Mitogen-Activated Protein Kinase; NF-B, Nuclear Factor-B; PI3K, 
Phosphatidyl Inositol 3-Kinase; PKA, Protein Kinase A; PLC, Phospholipase C; SERM, Selective 
Estrogen Receptor Modulator; Sp1, Specific Protein 1.  
they confirm that this action is induced by a membrane ER. The existence of membrane 
estrogen receptor was discovered in the late 1970s in endometrial cells (Pietras & Szego, 1977). 
Various studies tempted to show that these membrane receptors are structurally similar to the 
classical cytoplasmic ER and that the  and  forms are represented (Chambliss & Shaul, 2002; 
Pappas et al., 1995; Razandi et al., 1999). More recently, a novel isoform of ER was 
highlighted: ER36. This 36 kDa protein lacks the trans activation domains AF-1 and AF-2 and 
has a DBD and a partial LBD, suggesting a membrane localization for this isoform (Wang et 
al., 2006). Also, estrogen binding sites localized at the membrane and the cytoplasm were 
detected in MCF-7 (Harrington et al., 2006). Since ER does not have a transmembrane domain, 
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it appears that palmitoylation of the classical form of the receptor is necessary for its 
membrane addressing (Acconcia et al., 2005; Ellmann et al., 2009). In addition, it has been 
demonstrated that ER could be anchored to the plasma membrane through interactions with 
many membrane proteins such as caveolin 1 and 2, striatine or with adapter proteins like Shc 
and p130 Cas (Crk -associated substrate) (Cheskis et al., 2007). 
2.3.4 Ligand-independent signaling pathway 
In absence of 17-E2, ER can be activated by phosphorylation via protein kinases A or C by 
extracellular signals like growth factors or cytokines, neurotransmitters, or by cell cycle 
regulators (Le Goff et al., 1994). Epidermal growth factor (EGF) mimics the effects of 17-E2 
in the mouse uterus. Similarly, insulin, insulin-like growth factor-I (IGF-I), dopamine or 
transforming growth factor- (TGF-) may activate ER. The main targets of these growth 
factors are the many serine residues present in the AF-1 domain of ER particularly Ser118 
and Ser167 (Nilsson et al., 2001).  
In summary, estrogens are involved in many signaling pathways, allowing fine control of 
cell and tissue functions.  
3. Estrogen involvement in osteoarthritis 
3.1 Epidemiological observations and clinical data 
OA is a worldwide public health problem which may affect different sites of the skeleton. In 
the Western world, at least 10% of the population present OA symptoms and 80% of the 
population will be potentially affected after the age of 70 years.  Knee OA represents one of 
the major causes of morbidity and disability in relation to the worsening of quality of life. 
Pathogenesis of knee OA involves multiple factors including gender, weight, and genetics. 
Association between OA and estrogen deficiency during menopause has been firstly evoked 
by Cecil & Archer in 1925 following clinical observation.  
The hypothesis that estrogen deficiency may promote the development of OA has then 
been relied on the results of observational epidemiological studies. It is known that the 
frequency of knee OA is higher in women than in men; it is worsened after menopause and 
is lower in women receiving hormone replacement therapy (HRT) (Oliveria et al., 1995; 
Wilson et al., 1990). Although contradictions exist, some studies have shown that 
hysterectomy may also be associated with OA suggesting the potential role of estrogens to 
prevent these age-related diseases (Inoue et al., 1995; Spector et al., 1988; Spector et al., 1991). 
In addition, women with metastatic breast cancer when treated with aromatase inhibitors 
develop joint pains and cessation of aromatase inhibitors therapy resolved this joint pain 
(Burstein & Winer, 2007; Crew et al., 2007); aromatase inhibitors are widely used as adjuvant 
therapy in postmenopausal women with ER positive breast cancer (for review see Moslemi 
& Seralini, 2005). Moreover, an association of estrogen receptor (ER and ER) 
polymorphisms has been found in patients with OA compared to unaffected subjects. All 
these data suggest a protective role of estrogen and HRT on OA through functional isoforms 
of ER. Such a protective effect of estrogen on the development of OA may suggest two 
potential mechanisms: a direct effect on cartilage and an indirect effect through 
modifications of sub-chondral bone remodelling. Nevertheless, some clinical studies based 
on symptomatic parameters failed to report any effect of HRT on cartilage metabolism, 
that’s why further studies are required to clearly demonstrate beneficial effects of estrogens 
on molecular regulations of articular cartilage homeostasis. 
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3.2 Biological in vivo and in vitro studies 
In vivo animal studies indicate that estrogens may have a protective effect against OA, 
reversing or reducing the cartilage degradation in ovariectomized mice, rats, sheeps and 
monkeys (Cuzzocrea et al., 2003; Ham et al., 2002; Høegh-Andersen et al., 2004; Oestergaard 
et al., 2006). However, the way by which estrogens act to prevent the pathogenesis of OA in 
these models remains unclear. It is supposed that estrogens prevent cartilage degradation by 
increasing production of growth factors such as insulin growth factor-I (IGF-I) and 
suppressing pro-inflammatory cytokines expression such as interleukin-6 (IL-6). A few data 
exist about the role of estrogen in regulating the synthesis of matrix compounds. In vivo, 
17-E2 prevents the degradation of collagen type II in the women treated with HRT 
(Mouritzen et al., 2003) but in vitro, it does not seem capable of modulating neosynthesis nor 
secretion of type II collagen in articular chondrocytes in primary culture (Ab-Rahim et al., 
2008; Claassen et al., 2006). The measurement of serum C-terminal telopeptide of type II 
collagen (CTX-II) in bovine articular cartilage explants has determined that 17-E2 
significantly protected the cartilage degradation induced by tumor necrosis factor- (TNF-) 
and oncostatin M (Oestergaard et al., 2006). In similar ex vivo experiments, 17-E2 can 
increase glycosaminoglycan (GAG) content of articular explants (Englert et al., 2006). 
Finally, the double invalidation of ER and ER gene receptors (double knock-out ER -/-, 
ER -/-) in mice aged of 6 months increases the number and size of osteophytes as well as a 
thinning of the sub-chondral plate, without changing the cartilage degradation (Sniekers et 
al., 2009). We demonstrated recently that 17-E2 (the most potent among all estrogens) at 
physiologic doses, and ER66 (wild type receptor) but not ER46 (AF-1 deleted receptor) 
could up-regulate at both mRNA and protein levels UDP-glucose dehydrogenase (UDPGD) 
in primary cultured articular chondrocytes via specific protein 1 (Sp1) binding sites (Maneix 
et al., 2008). This enzyme is responsible of UDP-glucuronate synthesis which is the main 
component of GAG chains polymerization in cartilage: it plays an essential role in the 
elongation of GAG chains and their attachment to the axial protein of proteoglycans (PGs). 
Its decarboxylation provides UDP xylose, which serves to anchor chains of chondroitin 
sulfate (CS), dermatan sulfate (DS) and heparan sulphate (HS). Moreover, we also 
established that 17-E2 increases the gene expression of type II collagen (COL2A1), the main 
collagen of hyaline cartilage, via trans activation domains AF-1 of ER66 in coordination 
with the transcription factors Sp1, Sp3, p300 and Soxs (Maneix et al, 2010). It would thus be 
a genomic mechanism ERE-independent. Finally, our preliminary results also showed that 
phytoestrogens such as apigenin and genistein could up-regulate the expression of UDPGD 
(unpublished data).  
Overall, these data indicate that estrogen/phytoestrogens and their receptors can be 
considered as potent regulators of chondrocyte homeostasis and are pro-anabolic for 
extracellular matrix synthesis. This may have potential applications in the tissue engineering 
of articular cartilage and offer new perspectives to prevent and/or to treat OA. 
4. Mechanisms of estrogen action in OA 
4.1 Effects on growth factors and cytokines 
17-E2 can firstly interact with pathways affecting the synthesis and secretion of the key 
growth factors involved in the regulation of cartilage metabolism. So, TGF- expression in the 
iliac crest chondrocytes is influenced by 17-E2 in a biphasic manner: low concentrations of 
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17-E2 increase TGF- expression whereas supra-physiologic doses decrease strongly its 
expression (Saggese et al., 1993). The concept of dose-dependence is confirmed by the majority 
of the studies on 17-E in the articular cartilage where physiological doses of the hormone 
show to be protective when considering the structural integrity of tissue while supra-
physiologic concentrations are often deleterious (Richette et al., 2003) (Fig. 3). Experiments on 
chondrocytes from ovariectomized monkeys treated with 17-E showed that this hormone 
increases concomitantly the expression of the binding protein of IGF-I (IGFBP-2) and synthesis 
of PG (Richmond et al., 2000). In addition, the synovial fluid of these animals contains IGF-I 
twice more than untreated animals. Thereafter, it was shown that estrogen deficiency increases 
the sensitivity of cell response to certain pro-inflammatory cytokines through an increase in 
the number of receptors or cytokine cofactors amplifying consequently the effects of catabolic 
cytokines in these cells. Estrogen treatment in ovariectomized animals significantly reduced 
the production and secretion of pro-inflammatory cytokines in articular chondrocytes. This 
anti-inflammatory effect of 17-E2 was highlighted by Le Bail et al. (2001) who showed that the 
localized production of 17-E2 by synovial cells has inhibited the IL-6 secretion by articular 
chondrocytes. In addition, 17-E2 can also reduce production of pro-inflammatory 
prostaglandins through a decrease in the mRNA steady-state levels of cyclooxygenase-2 
(COX-2) in bovine articular chondrocytes (Morisset et al., 1998). 
4.2 Metalloproteinases (MMPs) expression and activity 
The majority of the beneficial effects of 17-E2 in articular chondrocytes is focused on the 
inhibition of catabolic pathways. Thus, Lee et al. (2003) found that 17-E2 decreases the 
secretion of the metalloproteinase MMP-1 in human osteoarthritic articular chondrocytes. In 
addition, 17-E2 can antagonize the degradation of PGs and the expression and activity of 
MMP-1, MMP-3 and MMP-13 enzymes induced by IL-1 in rabbit articular chondrocytes 
(Richette et al., 2004). Especially, the effects of 17-E2 on the expression of MMP-13 seem to be 
transmitted through the indirect binding of ER66 at an AP-1 site in the promoter of MMP-13 
gene (Lu et al., 2006). Like the mode of action of 17-E2 on the expression levels of TGF-, the 
effects of the hormone on the expression of MMPs and their inhibitors TIMPs (tissue inhibitors 
of MMPs) appear to be dose-dependent. Low doses of 17-E2 decreased MMP-1/TIMP-1 and 
MMP-3/TIMP-1 ratios while higher concentrations have the opposite effect (Song et al., 2003). 
4.3 Anti-oxidant effects 
The generation of reactive oxygen species (ROS) contributes actively to the cartilage ECM 
degradation in OA, in particular by inducing a decrease in the synthesis of PGs. However, 
due to the structure of their phenol nuclei, 17-E2 and its metabolites have anti-oxidant 
features (Liehr & Roy, 1998) that protect the cartilage degradation induced by ROS 
(Claassen et al., 2005). It is now established that 17-E2 is a modulator of the redox status of 
chondrocytes. 
During the arthritic process, overproduction of nitric oxide (NO) is a consequence of the 
action of proinflammatory cytokines such as IL-1 or TNF- that promote the activation of 
inducible nitric oxide synthase (iNOS) in OA chondrocytes. The iNOS gene is under the 
control of an estrogen-dependent promoter. Indeed, estrogen deficiency activates 
transcription of this promoter while a replacement therapy by 17-E2 inhibits it in 
ovariectomized mice (Cuzzocrea et al., 2003). 17-E2 can counteract the deleterious effects 
induced by IL-1 in rabbit articular chondrocytes by reducing the binding capacity of NF-B  
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Fig. 3. Role of 17-E2 and estrogen receptor ER /ER on joint cartilage homeostasis. 
Col II, type II collagen; IGF-I, Insulin-like Growth Factor-I; IL, Interleukin; iNOS, Inducible Nitrogen 
Oxide Synthase; MMPs, Metalloproteinases; PGs, Proteoglycans; ROS, Reactive Oxygen Species; SERM, 
Selective Estrogen Receptor Modulators; TIMPs, Tissue Inhibitors MMPs; TGF-, Transforming Growth 
Factor-; TNF-, Tumor Necrosis Factor-; UDPGD, Uridine Diphospho-Glucose Dehydrogenase. The 
roles of SERM and phytoestrogens need to be clarified. 
in the promoter of iNOS gene resulting in inhibition of nuclear translocation of this factor 
(Richette et al., 2007). This results in an inhibition of iNOS gene transcription and a 
subsequent reduction in NO production by chondrocytes. 
4.4 Matrix components turn-over 
To better understand the physiopathology of articular cartilage in osteoarthritis, Høegh-
Andersen et al. (2004) have validated an experimental model of ovariectomized rats with 
modification in cartilage structure representative of in vivo pathological changes observed in 
early human osteoarthritis. In animals aged from 5 to 7 months, estrogen deficiency 
increases the erosion of the articular surface and accelerates the renewal of matrix 
molecules. This animal model also showed that the effectiveness of HRT in the prevention of 
cartilage loss is increased when estrogen is administered to the animal from its operation 
and not after a period of 3 weeks (Oestergaard et al. 2006). These works need to be 
compared with the many epidemiological data which showed that the benefits of HRT are 
strengthened when patients are treated at the first signs of menopause and continued their 
treatment over a period exceeding 5 years. The importance of prevention in the treatment of 
damaged cartilage appears essential.  
4.5 Sub-chondral bone regulation 
Within the joint, cartilage is not the only target tissue for estrogens. 17-E2 also controls the 
renewal of the sub-chondral bone by maintaining a balance between the two players in bone 
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remodeling: osteoblasts that synthesize bone matrix and osteoclasts that are responsible for 
the resorption (bone loss) of existing bone. Estrogens inhibit osteoclasts activation and are 
therefore considered as inhibitors of bone resorption. The predominant mechanism that 
appears to be involved is the inhibition of IL-6 synthesis, the main cytokine involved in the 
activation of resorption. This inhibition of IL-6 synthesis by estrogens is mediated through 
the modification of NF-B binding on IL-6 gene promoter; there is no direct binding of ER to 
DNA (Ray et al., 1994). Consequently, an increase of bone resorption, generally favoring the 
occurrence of osteoporosis, is frequently seen in women after menopause which is related to 
the decrease of circulating estrogen levels during this period (Reginster et al., 2003). In this 
context, HRT could effectively prevent postmenopausal osteoporosis. 
Paradoxically, the frequency of OA and osteoporosis in postmenopausal women are most 
often inversely correlated, as reflected in the levels of osteocalcin, a marker of bone 
turnover, which are generally lower among women with OA than women without OA (for 
review: Dequeker et al., 2003). Patients suffering from OA of the knee are generally less 
subjected to bone loss. The increase in bone mass is a risk factor for incidence and 
development of knee and hip osteoarthritis. It was suggested that an increase in bone 
density in the area of the sub-chondral bone may induce bone stiffness and accelerate 
cartilage destruction. Thus, high bone density is associated with an increase of OA 
prevalence of the hip, hand and knee in postmenopausal women. However, high bone 
density increases risk of knee OA but protects against the progression of the disease once it 
is established. Therefore, bone loss in people with OA which is already established 
accelerates the progression of the disease. Indeed, Jacobsen et al. (2007) showed that the 
reduction of intra-articular space in the hip was correlated with the decrease in mineral 
density of sub-chondral bone in postmenopausal women. It was suggested that the 
alteration of bone structure can cause changes in the load distribution within the joint and 
promote the development of OA (Sniekers et al. 2008). In this case, the favorable effect of 
estrogen on cartilage may be due in part to the anti-resorption effect of 17-E2 on bone. 
5. Phytoestrogen and Selective Estrogen Receptor Modulators (SERM) 
During the second half of the 20th century, HRT has been repeatedly promoted as the only 
pharmacological approach allowing a global prevention of all disorders related to or 
potentiated by estrogen deprivation. Recently, the risk/benefit profile of HRT has been 
severely challenged because of apparent increased risks of invasive breast cancer, coronary 
heart disease events, stroke and pulmonary embolism among treated women. These new 
findings imply a careful reassessment of the current evidence justifying the prescription of 
HRT for the prevention of the management of chronic disorders.  The many contradictions 
recorded concerning benefit/risk effects of HRT are often related to differences in 
methodology and criteria used in measuring the effects of estrogen therapy in clinical 
studies. Indeed, analysis based strictly on symptomatic parameters showed that HRT had 
no effect or even adverse effects on the progression of OA (Von Muhlen et al., 2002). 
Conversely, more advanced techniques of magnetic resonance imaging showed that 
recipients of long term HRT (5 years or more) had a volume of articular cartilage largest in 
the knee than women having never taken any treatments (Wluka et al., 2001). As to the 
evolution of medical imaging techniques and advances in the diagnosis of OA, it appears 
that estrogens have a strong potential for preventing disease and preserving the structural 
integrity of the articulation among postmenopausal women. Thus, recent clinical trials of 
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consortium “Women's Health Initiative” showed that women treated with equine estrogens 
over a period of 7 years had 17% lower risk to undergo a hip replacement compared to 
control group (Cirillo et al., 2006). Finally, an in vivo study performed on 180 ovariectomized 
monkeys for 3 years found that HRT reduced the severity of arthritic lesions, through 
attenuation of the PGs loss and reducing the number of osteophytes in these animals (Ham 
et al., 2002). Given its chondroprotective potential, it would seem that HRT is capable of 
modulating chondrocyte metabolism. Studies have also shown that SERM and 
phytoestrogens may have beneficial effect on cartilage metabolism and to alleviate OA 
symptoms (Arjmandi et al, 2004; Bassleer et al., 1996; Guiducci et al., 2005; Tsai et al., 1992). 
It has been shown that when administered at a clinically relevant dose in young male rats, 
tamoxifen causes persistent retardation of longitudinal and cortical radial bone growth 
through systemic suppression of IGF-I production and local effects on the growth plate 
cartilage; it increases in chondrocytes proliferation/apoptosis and decreases the number of 
hypertophic chondrocytes (Karimian et al., 2008). Similarly, raloxifen could act as estrogen 
agonist on the growth plate of ovariectomized immature rabbits, accelerating growth plate 
senescence and thus hastening epiphyseal fusion (Nilsson et al, 2003). 
Besides estrogens, natural molecules such as phytoestrogens (estrogen-like compounds in 
plants) sharing structural and functional homologies with endogenous estrogens, could also 
act (even thought at micromolar concentrations) as agonists and/or antagonists in hormone-
sensitive target cells. Scientists are now interested in the tissue-selective activities of 
phytoestrogens considering anti-estrogenic effects in reproductive tissue that could help to 
reduce the risk of hormone-associated cancers (breast, uterine, ovarian, and prostate), while 
estrogenic effects on bone and cardiovascular system for instance could favor the 
maintenance of bone density and protect against atherosclerosis respectively. Moreover, it 
has been suggested that the consumption of dietary phytoestrogens (soja isoflavones, 
lignans, etc.) may have beneficial effects on bone health at all stages of life. That’s why 
phytoestrogens have aroused much interest as potential substitutes in HRT of 
postmenopausal women, but they require much further investigation regarding their 
mechanism of action and their safety. Like estrogens, phytoestrogens may act via genomic 
and non genomic pathways. The most relevant molecular actions of phytoestrogens are 
those mediated by ERs. They may act on protein tyrosine kinase, MAP kinase, 
topoisomerase II and at all stages of cell cycle and apoptosis. They can also change the 
response to growth factors and cytokines. Genistein up to 100 M reduces the production of 
lipopolysaccharide (LPS)-stimulated pro-inflammatory molecules (COX-2, NO) but not that 
of COX-1 responsible of releasing prostaglandins in normal human chondrocytes 
(Hooshmand et al., 2007). When tested on human chondrocytes and chondrocytic cell line 
CHON-002, bavachin, a flavonid phytoestrogen isolated from Psoralea corylifolia, potentially 
protected cartilage from inflammation-mediated damage in joints of OA through decreasing 
IL-1beta-induced activation of IKK-IB alpha-NF-B signaling pathway (Cheng et al., 2010). 
Formononetin, a phytoestrogen isolated from Astragalus membranaceus showed to have 
biphasic positive effects on human normal osteoblasts and OA sub-chondral osteoblasts by 
modifying their biological synthetic capacities (Huh et al., 2010). Using female bovine 
articular chondrocytes, it has been demonstrated that the stimulating effect of insulin on 
GAGs sulfate incorporation was enhanced significantly after preincubation of cells with 10-11 
-10-5 M daidzein or 10-9 -10-5 M genistein but not by 17-E2 (Claassen et al., 2008). More 
recently, xanthohumol, a prenylflavonoid extracted from hop, showed to prevent 
hyaluronan overproduction as well as PG and collagen loss in bovine chondrocytes; 
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hyluronan overproduction is considered as an early reaction in OA followed by PG loss and 
collagen degradation (Stracke et al., 2001).  However, additional research is critical to 
determine how phytoestrogens act on cartilage cells to obtain a more complete 
understanding of the effects. 
6. Conclusion 
From epidemiological, clinical, in vivo and in vitro studies, a huge amount of data consistent 
with the fact that estrogens and their receptors can now be considered among the main 
players involved in the chondrocyte homeostasis and participate in cartilage protection from 
degradation and erosion occurring during menopause. Indeed, once ligand/ER complex is 
formed, estrogens such as 17-E2 could act with ER to induce or to inhibit trans activation of 
target genes of chondrocytes, the predominant cells of articular cartilage allowing 
expression of the specific chondrogenic markers such as UDPGD, PGs, type II collagen or 
inhibition of catabolic markers such as metalloproteinases and interleukins. There are 
different pathways by which estrogen and ER may interact with target genes in 
chondrocytes but it seems that Sp1 mediated trans activation being preferentially used in 
this cell type. In this mechanism ER needs AF-1 sequence (ligand-independent trans 
activation domain) to exert its action on GC boxes via Sp1 in target genes. In addition, some 
molecules sharing structural and functional features with estrogens like SERM and 
phytoestrogens can mimic estrogenic action and are therefore useful to repair cartilage 
erosion or might contribute at least to protect premenopausal joint cartilage and to maintain 
its homeostasis in a prevention strategy but these molecules need further investigation and 
deserves more attention from the scientific community to prove their safety and efficacy. 
7. Key points 
Osteoarthritis, cartilage, chondrocytes, estrogens, phytoestrogens, selective estrogen 
receptor modulators, hormone replacement therapy, menopause. 
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